Bepirovirsen not checked
GSK · GSK3228836 · ISIS 505358
FollowEvery change as it happens, and a Monday email
Trials
6 active
17 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “No study medication will be administered in this study. Eligible participants who received bepirovirsen in the parent studies will be included.”In the company’s words, NCT07908459 on ClinicalTrials.gov
- Tested for
- Hepatitis B (6 trials), Chronic Hepatitis B Virus Infection
- Main trialPhase 4
- “This multi-country, longitudinal follow-up study will enrol adults with chronic hepatitis B (CHB) who previously participated in the Phase III B-Well-1 ((202009: NCT05630807) or B-Well-2 (219288: NCT05630820) studies, received 24 weeks of Bepirovirsen treatment, and achieved hepatitis B surface antigen (HBsAg) levels less than or equal to (\<=) 100 International units per millilitres (IU/mL) at Week 72 without achieving functional cure. No investigational treatment will be administered in this study. Participants will be followed approximately every 6 months for up to 4 years, and…”In the company’s words, NCT07908459 on ClinicalTrials.gov
- Other names
- GSK3228836 · IONIS-HBVRx · ISIS 505358
Other drugs for Hepatitis B
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- In-House Recombinant Hepatitis B vaccinePT Bio Farma · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- LBVDLG Chem · Phase 2/3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
Coming up5
- 30 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 22 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 24 Jan 2029Phase 2 trial completes · ClinicalTrials.gov
- 3 Dec 2030Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | 3 Dec 2030 | B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants | |
| Phase 2Active, not recruiting | 22 Apr 2027 | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | |
| Phase 2Active, not recruiting | 31 May 2027 | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | |
| Phase 2Active, not recruiting | 24 Jan 2029 | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) | |
| Phase 1Active, not recruiting | 3 Mar 2026 | A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease | |
| Phase 1Not yet recruiting | 30 Mar 2027 | A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants | |
| Phase 3Completed | 3 Nov 2025 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) | |
| Phase 3Completed | 11 Nov 2025 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) | |
| Phase 2Completed | 18 Dec 2019 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection | |
| Phase 2Completed | 18 Mar 2022 | A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) | |
| Phase 2Completed | 17 Feb 2023 | Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB) | |
| Phase 2Completed | 30 Nov 2023 | A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B | |
| Phase 2Completed | 5 Aug 2025 | A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy | |
| Phase 1/2Terminated | 19 May 2025 | Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection | |
| Phase 1Completed | 12 May 2022 | Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment | |
| Phase 1Completed | 3 May 2024 | A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants | |
| Phase 1Completed | 28 Apr 2025 | Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026